GlassScriptPhysician profile
Colleen Wallace
NPI 1568187904
$2,393.80
in general payments reported to CMS, 2019-2025
28 companies · $1,316 in 2025
The $1,316 reported for 2025 was more than what 87% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $538 · 2024: $539 · 2025: $1,316.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,394.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,393.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $652.54 | 2023-2025 | |
| Currax Pharmaceuticals LLC | $305.44 | 2023-2024 | Onzetra Xsail |
| Lundbeck LLC | $282.96 | 2024-2025 | Vyepti |
| Tg Therapeutics, INC. | $281.28 | 2024-2025 | |
| Pfizer INC. | $119.77 | 2023-2025 | |
| Merz Pharmaceuticals, LLC | $84.71 | 2023-2024 | Xeomin |
| Emd Serono, INC. | $67.50 | 2024-2025 | |
| Teva Pharmaceuticals USA, INC. | $63.46 | 2023-2025 | Ajovy |
| Genentech USA, INC. | $49.10 | 2025 | Ocrevus Zunovo |
| Biogen, INC. | $38.72 | 2025 | Vumerity |
| Neurelis, INC. | $36.80 | 2025 | Valtoco |
| Spr Therapeutics, INC | $33.60 | 2025 | Sprint Pns System |
| Alexion Pharmaceuticals, INC. | $30.30 | 2025 | Ultomiris |
| Impel Pharmaceuticals INC. | $29.66 | 2023 | Trudhesa |
| Novartis Pharmaceuticals Corporation | $29.41 | 2025 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ani Pharmaceuticals, INC. | $27.40 | 2025 | Purified Cortrophin Gel |
| Takeda Pharmaceuticals U.S.A., INC. | $25.24 | 2025 | Hyqvia |
| Csl Behring | $25.01 | 2025 | Hizentra |
| Bioventus LLC | $24.70 | 2025 | Durolane |
| Gemini Mountain Medical, LLC | $24.65 | 2025 | |
| Lilly USA, LLC | $24.40 | 2024 | Reyvow, Emgality |
| Azurity Pharmaceuticals, INC. | $24.19 | 2025 | Horizant |
| Depuy Synthes Sales INC. | $22.15 | 2025 | Monovisc, Orthovisc |
| Amgen INC. | $20.73 | 2025 | Uplizna |
| Sk Life Science, INC. | $20.72 | 2025 | |
| Celgene Corporation | $17.58 | 2025 | Zeposia |
| Tonix Medicines, INC. | $16.09 | 2024 | Zembrace Symtouch |
| Eisai INC. | $15.69 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Colleen Wallace listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.